Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 4Neoplasms 3Anxiety Disorders 3Motor Activity 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Vomiting 1Triple Negative Breast Neoplasms 1Treatment Adherence and Compliance 1Sclerosteosis 1Recurrence 1Periodontitis 1Periodontal Diseases 1Patient Compliance 1Osteoporosis, Postmenopausal 1Obesity 1Nausea 1Lymphedema 1Liver Cirrhosis 1Leukemia, Promyelocytic, Acute 1Inflammation 1Gastrointestinal Neoplasms 1Feeding Behavior 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Weights and Measures × Clear all
NCT02750358 2025-06-22

Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
50 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡